MX360141B - Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. - Google Patents
Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.Info
- Publication number
- MX360141B MX360141B MX2014009751A MX2014009751A MX360141B MX 360141 B MX360141 B MX 360141B MX 2014009751 A MX2014009751 A MX 2014009751A MX 2014009751 A MX2014009751 A MX 2014009751A MX 360141 B MX360141 B MX 360141B
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- same
- treat cancer
- avb6
- integrin avb6
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 102000006495 integrins Human genes 0.000 title abstract 2
- 108010044426 integrins Proteins 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261600499P | 2012-02-17 | 2012-02-17 | |
| US201261602511P | 2012-02-23 | 2012-02-23 | |
| PCT/US2013/026087 WO2013123152A2 (en) | 2012-02-17 | 2013-02-14 | ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014009751A MX2014009751A (es) | 2015-02-24 |
| MX360141B true MX360141B (es) | 2018-10-24 |
Family
ID=48984888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014009751A MX360141B (es) | 2012-02-17 | 2013-02-14 | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US9493566B2 (enExample) |
| EP (1) | EP2814509B1 (enExample) |
| JP (1) | JP6273214B2 (enExample) |
| KR (1) | KR102084806B1 (enExample) |
| CN (2) | CN105017420B (enExample) |
| AU (1) | AU2013221585B2 (enExample) |
| BR (1) | BR112014019861A2 (enExample) |
| CA (1) | CA2862319C (enExample) |
| EA (1) | EA031069B1 (enExample) |
| IL (1) | IL233742B (enExample) |
| MX (1) | MX360141B (enExample) |
| SG (1) | SG11201404354UA (enExample) |
| WO (1) | WO2013123152A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3170888A1 (en) | 2008-05-23 | 2017-05-24 | Siwa Corporation | Methods and compositions for facilitating regeneration |
| WO2015049280A1 (en) * | 2013-10-01 | 2015-04-09 | Medimmune Limited | Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer |
| JP6747971B2 (ja) | 2013-10-15 | 2020-08-26 | シアトル ジェネティックス， インコーポレイテッド | 改善されたリガンド−薬物コンジュゲート薬物動態のためのｐｅｇ化薬物−リンカー |
| ES2885686T3 (es) | 2014-02-17 | 2021-12-15 | Seagen Inc | Conjugados anticuerpo-fármaco hidrófilos |
| WO2015164627A1 (en) * | 2014-04-23 | 2015-10-29 | Discovery Genomics, Inc. | Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer |
| BR112017005517A2 (pt) | 2014-09-19 | 2017-12-05 | Siwa Corp | anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| US11229708B2 (en) | 2015-12-04 | 2022-01-25 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
| MX2018009988A (es) | 2016-02-19 | 2018-12-17 | Siwa Corp | Metodo y composicion para tratar el cancer, destruir las celulas cancerosas metastasicas y evitar la metastasis del cancer usando anticuerpo para productos finales de glicacion avanzada (age). |
| EP3433278A4 (en) | 2016-03-25 | 2019-11-06 | Seattle Genetics, Inc. | METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF |
| CA3057829A1 (en) | 2016-04-15 | 2017-10-19 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
| CN109562152B (zh) | 2016-08-09 | 2024-04-02 | 西雅图基因公司 | 含有具有改善的生理化学性质的自稳定性接头的药物缀合物 |
| KR20190074292A (ko) | 2016-10-18 | 2019-06-27 | 시애틀 지네틱스, 인크. | 니코틴아미드 아데닌 디뉴클레오티드의 구제 경로 저해제의 표적화된 전달 |
| SI3535397T1 (sl) | 2016-11-01 | 2022-04-29 | Arrowhead Pharmaceuticals, Inc. | Ligandi alfa-V beta-6 integrina in njihove uporabe |
| WO2018107116A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby |
| JP7244987B2 (ja) | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | 多剤抗体薬物コンジュゲート |
| CN110430901B (zh) | 2017-03-24 | 2024-08-16 | 西雅图基因公司 | 制备葡糖苷酸药物-接头及其中间体的方法 |
| US10919957B2 (en) | 2017-04-13 | 2021-02-16 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| CN110799217A (zh) | 2017-04-27 | 2020-02-14 | 西雅图基因公司 | 季铵化烟酰胺腺嘌呤二核苷酸补救途径抑制剂缀合物 |
| CN111526880A (zh) | 2017-11-01 | 2020-08-11 | 箭头药业股份有限公司 | 整联蛋白配体及其用途 |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| WO2019164987A1 (en) | 2018-02-20 | 2019-08-29 | Seattle Genetics, Inc. | Hydrophobic auristatin f compounds and conjugates thereof |
| US20240199735A1 (en) * | 2019-07-22 | 2024-06-20 | The Methodist Hospital | Microfibrillar-Associated Protein 5 (MFAP5)-Targeting Monoclonal Antibodies and Methods for Use in Treating Cancer |
| US11827709B2 (en) | 2019-12-05 | 2023-11-28 | Seagen Inc. | Anti-AVB6 antibodies and antibody-drug conjugates |
| JP2023509760A (ja) | 2020-01-08 | 2023-03-09 | シンシス セラピューティクス，インコーポレイテッド | Ａｌｋ５阻害剤複合体およびその使用 |
| CN115955980A (zh) | 2020-04-10 | 2023-04-11 | 思进公司 | 电荷可变接头 |
| KR20230158005A (ko) | 2021-03-18 | 2023-11-17 | 씨젠 인크. | 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출 |
| PH12023552779A1 (en) | 2021-04-08 | 2024-04-15 | Arrowhead Pharmaceuticals Inc | Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use |
| KR20230171980A (ko) | 2021-04-20 | 2023-12-21 | 씨젠 인크. | 항체 의존성 세포 독성의 조절 |
| CN117580593A (zh) | 2021-05-28 | 2024-02-20 | 思进公司 | 蒽环霉素抗体结合物 |
| CN119278055A (zh) | 2022-03-17 | 2025-01-07 | 思进公司 | 喜树碱缀合物 |
| EP4634227A1 (en) | 2022-12-13 | 2025-10-22 | Seagen Inc. | Site-specific engineered cysteine antibody drug conjugates |
| EP4637731A1 (en) | 2022-12-21 | 2025-10-29 | Gilead Sciences, Inc. | Combination therapy for treating cancer |
| WO2024263932A2 (en) | 2023-06-23 | 2024-12-26 | Mythic Therapeutics, Inc. | Itgb6-binding proteins and uses thereof |
| WO2025149947A1 (en) | 2024-01-12 | 2025-07-17 | Seagen Inc. | Antibody-drug conjugates |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962643A (en) | 1991-07-11 | 1999-10-05 | The Regents Of The University Of California | Integrin β subunit and uses thereof |
| DE69840113D1 (de) | 1997-08-08 | 2008-11-20 | Univ California | Behandlung von Leberfibrose mit Anti-alpha V beta 6 Integrin Antikörpern |
| EP1385545B1 (en) * | 2001-04-30 | 2009-01-07 | Eli Lilly And Company | Humanized antibodies recognizing the beta-amyloid peptide |
| EP2287198A3 (en) * | 2002-03-13 | 2011-05-25 | Biogen Idec MA Inc. | Anti-alpha V beta 6 antibodies |
| UA90242C2 (ru) * | 2002-03-13 | 2010-04-26 | Байоджен Айдек Ма Инк. | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С αVβ6 |
| EP1492870A4 (en) | 2002-04-12 | 2005-08-03 | Raven Biotechnologies Inc | ANTIBODIES BINDING TO INTEGRIN-ALPHA-V-BETA-6 AND METHOD OF USE THEREOF |
| US7241598B2 (en) * | 2004-06-29 | 2007-07-10 | The Chinese University Of Hong Kong | Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering |
| JP2008515438A (ja) * | 2004-10-05 | 2008-05-15 | ワイス | 組換えタンパク質産生の改善方法および組成物 |
| HUE025449T2 (en) * | 2004-12-09 | 2016-04-28 | Janssen Biotech Inc | Immunoconjugates against Integrin, a method for their preparation and use |
| JP4949373B2 (ja) * | 2005-03-10 | 2012-06-06 | モルフォテック、インク． | 抗メソテリン抗体 |
| CN102875681A (zh) * | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
| CA2620641A1 (en) | 2005-08-31 | 2007-03-08 | Novo Nordisk Health Care Ag | Human fvii monoclonal antibodies binding the gla domain and use thereof |
| MX2009001293A (es) | 2006-08-03 | 2009-02-11 | Astrazeneca Ab | Anticuerpos dirigidos a (v(6 y usos de los mismos. |
| CL2007002225A1 (es) * | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
| EP2087008A1 (en) | 2006-10-19 | 2009-08-12 | The Regents of the University of California | TREATMENT AND PREVENTION OF CHRONIC ASTHMA USING ANTAGONISTS OF INTEGRIN alphaVbeta6 |
| CA2711557A1 (en) * | 2008-01-11 | 2009-07-16 | The University Of Tokyo | Anti-cldn6 antibody |
| JP2011509687A (ja) * | 2008-01-22 | 2011-03-31 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｒｏｎ抗体およびその使用 |
| WO2009119258A1 (ja) | 2008-03-27 | 2009-10-01 | テルモ株式会社 | 生体吸収性材料およびそれを用いた生体内留置物 |
| WO2009135953A2 (en) | 2008-05-09 | 2009-11-12 | Ablynx Nv | Amino acid sequences directed against integrins and uses thereof |
| JP2010210772A (ja) * | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| WO2011046309A2 (en) | 2009-10-12 | 2011-04-21 | Korea Research Institute Of Bioscience And Biotechnology | A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof |
| KR101138460B1 (ko) * | 2009-10-12 | 2012-04-26 | 한국생명공학연구원 | 항-ｆａｓｎ 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물 |
| MX361929B (es) | 2010-11-19 | 2018-12-19 | Eisai R&D Man Co Ltd Star | Anticuerpos anti-ligando de quimiocina cc 20 (ccl20) neutralizantes. |
| ES2875535T3 (es) | 2012-03-29 | 2021-11-10 | Biogen Ma Inc | Biomarcadores para su uso en aplicaciones de terapia de integrina |
-
2013
- 2013-02-14 EA EA201491541A patent/EA031069B1/ru unknown
- 2013-02-14 CN CN201510418545.9A patent/CN105017420B/zh active Active
- 2013-02-14 CN CN201380009160.6A patent/CN104220094A/zh active Pending
- 2013-02-14 SG SG11201404354UA patent/SG11201404354UA/en unknown
- 2013-02-14 AU AU2013221585A patent/AU2013221585B2/en not_active Ceased
- 2013-02-14 CA CA2862319A patent/CA2862319C/en active Active
- 2013-02-14 MX MX2014009751A patent/MX360141B/es active IP Right Grant
- 2013-02-14 JP JP2014557760A patent/JP6273214B2/ja not_active Expired - Fee Related
- 2013-02-14 WO PCT/US2013/026087 patent/WO2013123152A2/en not_active Ceased
- 2013-02-14 KR KR1020147025536A patent/KR102084806B1/ko active Active
- 2013-02-14 EP EP13749647.7A patent/EP2814509B1/en active Active
- 2013-02-14 US US14/378,746 patent/US9493566B2/en not_active Expired - Fee Related
- 2013-02-14 BR BR112014019861A patent/BR112014019861A2/pt not_active IP Right Cessation
-
2014
- 2014-07-22 IL IL233742A patent/IL233742B/en active IP Right Grant
-
2016
- 2016-09-07 US US15/258,699 patent/US20160376368A1/en not_active Abandoned
-
2019
- 2019-09-30 US US16/588,331 patent/US20200031938A1/en not_active Abandoned
-
2021
- 2021-01-08 US US17/144,869 patent/US20210340260A1/en not_active Abandoned
-
2023
- 2023-02-17 US US18/170,742 patent/US20230242648A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013221585B2 (en) | 2017-03-30 |
| US9493566B2 (en) | 2016-11-15 |
| KR102084806B1 (ko) | 2020-03-04 |
| US20230242648A1 (en) | 2023-08-03 |
| WO2013123152A3 (en) | 2014-11-13 |
| WO2013123152A2 (en) | 2013-08-22 |
| CN104220094A (zh) | 2014-12-17 |
| US20210340260A1 (en) | 2021-11-04 |
| CN105017420B (zh) | 2019-05-28 |
| MX2014009751A (es) | 2015-02-24 |
| EA201491541A1 (ru) | 2016-05-31 |
| US20160376368A1 (en) | 2016-12-29 |
| EP2814509B1 (en) | 2018-05-16 |
| SG11201404354UA (en) | 2014-10-30 |
| US20160009806A1 (en) | 2016-01-14 |
| CA2862319A1 (en) | 2013-08-22 |
| HK1211035A1 (en) | 2016-05-13 |
| JP6273214B2 (ja) | 2018-01-31 |
| JP2015509938A (ja) | 2015-04-02 |
| KR20140127875A (ko) | 2014-11-04 |
| EP2814509A4 (en) | 2015-12-09 |
| EA031069B1 (ru) | 2018-11-30 |
| BR112014019861A2 (pt) | 2017-07-04 |
| IL233742A0 (en) | 2014-09-30 |
| CA2862319C (en) | 2021-11-30 |
| AU2013221585A1 (en) | 2014-08-14 |
| EP2814509A2 (en) | 2014-12-24 |
| US20200031938A1 (en) | 2020-01-30 |
| CN105017420A (zh) | 2015-11-04 |
| IL233742B (en) | 2019-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX360141B (es) | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. | |
| MX2020010639A (es) | Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer. | |
| NZ702748A (en) | Cd33 antibodies and use of same to treat cancer | |
| PH12014501164A1 (en) | Anti-cd98 antibodies and methods of use thereof | |
| SG2014008304A (en) | C10rf32 antibodies, and uses thereof for treatment of cancer | |
| TN2015000396A1 (en) | Antibody drug conjugates | |
| MX2015012122A (es) | Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes. | |
| SG10201704992SA (en) | Lsr antibodies, and uses thereof for treatment of cancer | |
| MX375221B (es) | Composiciones que comprenden anticuerpos anti-molécula de adhesión celular relacionada con antígeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cáncer. | |
| MX366804B (es) | Translocaciones de la r-espondina y sus metodos de uso. | |
| HRP20220897T8 (hr) | Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka | |
| MX2016003129A (es) | Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano. | |
| MX2015007185A (es) | Uso de eribulina en el tratamiento de cancer de pecho. | |
| MX337577B (es) | Anticuerpos c-kit y usos de los mismos. | |
| MX2013006392A (es) | Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1. | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| UA117663C2 (uk) | Антиандроген для лікування неметастатичного кастраційно-резистентного раку передміхурової залози | |
| MX2015011518A (es) | Agentes de enlace de met y usos de los mismos. | |
| IN2014DN09717A (enExample) | ||
| MX353951B (es) | Anticuerpos de anti-teofilina y metodos de uso. | |
| MX362497B (es) | Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo. | |
| IL232339A0 (en) | 32rf10c antibodies, and their uses for cancer treatment | |
| TR201905240T4 (tr) | LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı. | |
| IL232340A0 (en) | lsr antibodies, and their uses for cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |